<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456586</url>
  </required_header>
  <id_info>
    <org_study_id>6002-US-005</org_study_id>
    <nct_id>NCT00456586</nct_id>
  </id_info>
  <brief_title>12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa</brief_title>
  <official_title>A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Pharmaceutical Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Pharmaceutical Development, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate
      the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with
      OFF phenomena advanced PD who were treated with levodopa/carbidopa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to
      evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in
      subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish the efficacy of 40 mg/day istradefylline for reducing motor symptoms and improving activities of daily living (ADL) in subjects with advanced PD treated with levodopa/carbidopa.</measure>
  </secondary_outcome>
  <enrollment>180</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6002 (istradefylline)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (step 1 and
             2).

          2. Modified Hoehn and Yahr Scale II-IV in the OFF state.

          3. Treated with levodopa/carbidopa for 1 year with a stable regimen for 4 weeks prior to
             randomization.

          4. Taking at least 4 doses of levodopa (3 doses if at least 2 doses containing slow
             release formulation) per day with predictable end of dose wearing off.

          5. Successfully completed Parkinson's disease patient diary training with at least 120
             minutes of OFF time per day.

          6. Stable regimen of other antiparkinson's disease medications for at least 4 weeks prior
             to randomization.

          7. At least 30 years of age and able to give written informed consent.

        Exclusion Criteria:

          1. Treatment with liquid levodopa/carbodopa within 4 weeks of randomization.

          2. Treatment with MAO inhibitors except selegiline.

          3. Treatment with centrally acting dopamine antagonists within 3 months (6 months for
             depot preparations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone,
             amoxapine.

          4. Neurosurgical surgery for Parkinson's disease.

          5. Atypical parkinsonism or secondary parkinsonism variants.

          6. Diagnosis of cancer or evidence of continued cancer within 5 years of enrollment or
             clinically significant illness of any organ system (e.g., ALT or AST &gt; 1.5 times the
             upper limit of normal).

          7. Mini-Mental Status Examination score of 25 or less.

          8. History of drug or alcohol abuse or dependence within 2 years.

          9. History of psychotic illness or seizures.

         10. Current clinically relevant depression disorder.

         11. History of neuroleptic malignant syndrome.

         12. Pregnant or lactating females. Women of child-bearing potential must use reliable
             method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sussman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Kirin Pharmaceutical Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Kyowa Pharmacuetical Inc.</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <keyword>Parkinson's disease</keyword>
  <keyword>Levodopa therapy</keyword>
  <keyword>End of dose wearing off</keyword>
  <keyword>Off time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Istradefylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

